Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Aagami Technology Licensing Presentation


Published on

Aagami Inc., a lifesciences consulting firm based in the suburbs of Chicago offers,

Technology Licensing Services 
Strategic Consulting Services and
Business & Market Research Services,

For Universities, Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies, in their initiatives with India, Asia and Emerging Markets.

Published in: Business
  • Be the first to comment

Aagami Technology Licensing Presentation

  1. 1. May 2015 Realizing Possibilities, Together Technology Licensing Services Meet us at:
  2. 2. Lifesciences Catalyst2 Aagami, Inc. A lifesciences consulting firm based in the suburbs of Chicago offers For Universities, Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies, in their initiatives with India, Asia and Emerging Markets. Technology Licensing Services Strategic Consulting Services Business & Market Research Services
  3. 3. Lifesciences Catalyst3 Needs of University Tech Transfer Offices Reach in the Investors’ world Access to Global Commercial Network Ability to speak “Investors’ language” Commercial Perspective on technology ‘Out of box’ thinking to widen market applications Ability to talk “Business’ language” Realistic Evaluation of commercial potential
  4. 4. Lifesciences Catalyst4 Technology Licensing Organizations (TLO) Concept TLOs – An emerging business model Complements/supplements Tech Transfer offices Licensing is the core business (‘raison d'être’) Have access to panel of experts Operate in the commercial markets Participate in trade shows and conferences Honed skills with multiple institutions/assignments Bring ‘out of the Box’ thinking
  5. 5. Lifesciences Catalyst5 Aagami TLO Services  Consolidate Industry demand  Consolidate available technologies  Evaluate Technologies to fit the demand  Evaluate Commercial Potential  Promote specific technologies Generate focused marketing brochures Broadcast to specific (relevant) companies Exchange information with the interested Help and support finalizing Licensing agreements
  6. 6. Lifesciences Catalyst6 Aagami TLO Framework  Wide-ranging Experience in the Biotech, Pharmaceutical and Medical Device industry, Infotech, Alternate Energy  Global Experience in Start-Ups, Licensing, M&As, Forming JVs and Investing  Good understanding of the ways of working (business culture) in multiple geographies such as US, Europe, Japan, India, and Israel  Extensive Global network including the top 200 Indian companies at CXO levels
  7. 7. Lifesciences Catalyst7 Sample list of Demand ‘Sweet Spots’  Novel Delivery Technologies  New Chemical Entities (NCE), Peptides, Biologics, Biosimilars, Vaccines in Therapeutic areas  Pain and Inflammation,  Diabetes and Metabolic disorders,  Anti-infective,  Oncology  Biomarkers for Oncology and Metabolic disorders  Synthesis Technologies for  Peptide,  Biosimilars and  Monoclonal Antibodies,
  8. 8. Lifesciences Catalyst8 Sample list of ‘sweet spots’ …contd  Pharmaceutical Technologies for  Analytical characterization of large molecules,  Cost-cutting in formulation and/or API manufacturing  for difficult to manufacture generics  Manufacturing Technologies in forgings and other automotive components  Novel Technologies in Solar energy, LEDs, Water purification  Technologies with space applications
  9. 9. 9 Sample list of Aagami Clients USA CreAgri CA New Heaven Pharma CT Advangene IL Loyola Univ. Chicago IL OncBioMune LA Dow Chemicals MI ScyFIX MN Penwest Corp. NY DesignMedix OR PLx TX International Phosphagenics Australia PeptiSyntha Belgium DelMar Pharma Canada Affitech Denmark Pieris Germany Merus Holland Venus Remedies India Opsona Ireland Toppan Japan Otago University New Zealand Lifesciences Catalyst Aagami has completed over 100 assignments for more than 50 clients in the last 12+ years.
  10. 10. Lifesciences Catalyst10 Sample of Aagami contacts in India We are connected at CXO Level of TOP 100 Lifesciences companies in India. Some of the popular names are below. Biocon Intas Sun Pharma Cadila Lupin Themis Cipla MicroLabs Torrent Pharma Dr Reddys Piramal USV Glenmark Reliance Wockhardt Hetero Drugs Strides Zydus
  11. 11. Lifesciences Catalyst11 Aagami brings  Deep Understanding of business and socio-cultural differences in ways of working  Extensive network with Top LifeSciences companies at CXO levels  Global Deal experience mainly with Western, Japanese and Indian industry  Aagami Partners bring value of combined experience of over 150 years.  Focus on client needs, objectives, success and work as an extension of client’s own team.
  12. 12. Lifesciences Catalyst12 Our Consulting Approach Setup • Understand and capture important details about the asset/technology • Prepare ‘Elevator Pitch’ (EP) customized to specific business culture • Identify relevant companies from our database and resources Prospect • Broadcast EP to Relevant Companies • Follow-up with phone calls and emails • Coordinate CDAs with interested Companies • Supply further info through emails • Organize conference calls for clarifications Finalize • Organize Road show • Manage appointments with right executives • Coordinate the logistics of the road show • Advise on structuring the deal • Support in negotiations (most critical)
  13. 13. Why Work with Aagami Approach Working with Aagami • Verified and Reliable Partner • Leverage Deep Connections of Aagami • Faster Results • Significant Savings of time and effort (=cost) • Deal experience and existing relationships with Industry • Proven track record Doing it Yourself (DIY) • Spend Considerable more time, valuable resource and money • Opportunity Cost • Uncertainty on Results • Less understanding of market dynamics • No Existing Relationship with companies in Target Geographies © Aagami, Inc. 2015 | All rights reserved | 13
  14. 14. Lifesciences Catalyst14 Working with Aagami- Engagement Model  Dedicated Teamwork (40-80 Hours/month)  Small monthly ‘binding’ fee for first 6 months  Success fee based on the modified Lehman’s formula Aagami’s prime focus is CLIENT SUCCESS as that's how we Succeed
  15. 15. Lifesciences Catalyst15 Aagami Leadership Team 1 of 2 Dinesh Jain – Founder CEO • A business leader in Science and technology industry since 1984 with global experience in starting and managing several technology companies. Has held positions of CEO, President, Vice President. Is a prolific entrepreneur. Has executed several dozen international deals across 4 continents. He is a regular speaker in International conference son Life Sciences Business with India, and also on board of several consulting and research companies Dr. Mahendra Shah, Ph D – Scientific & Business • A veteran Scientific leader in Bio-Pharmaceutical field since 1968 . After his PhD, he has worked with some of the top notch companies like Bristol, Squibb, Schering, Lyphomed, Fujisawa, EJ Financials, First Horizon, NextWave. Mahendra is an active Investor in BioPharmaceutical field and is on the Board of several companies across the country. Michael S. Rosen - Business • A Senior executive and entrepreneur working globally since 1974. Managed 3 multinational pharma and agro-science companies working in Europe, Latin America, Japan, Canada, Asia and Israel. CEO experience starting and growing several biotech and medical device companies in the U.S. and Europe, raising more than $50 million in equity and taking 1 company public. Economic development expertise creating and expanding vibrant science parks and life-science ecosystems as public-private partnerships
  16. 16. Lifesciences Catalyst16 Aagami Leadership Team 2 of 2 Dr. Aman Ahuja, M.D., F.P.M., F.R.C.A. – Medical • A specialist pain medicine physician and consultant at the North Queensland, Australia. MD Anaesthesia from India, Fellow of Royal College of Anaesthetists, Ireland, Masters in Pain Medicine from UK, Fellow of Tess Cramond Multidisciplinary Pain Centre, Australia; Dr. Ahuja has focus on clinical practice, research and advancing rational therapies for a diverse range of conditions. His current interests include studying the expanding role of radiofrequency in field of Pain Medicine. Dr. Ahuja uses a compassionate and multidisciplinary approach in his well known practice as a Pain Specialist and Anesthetist. Dr. Shridhar Andurkar, Ph D – Scientific • Chair and Associate Professor of Pharmaceutical sciences at Midwestern University, Chicago College of Pharmacy, is a Ph D from Auburn University in Medicinal Chemistry, Conducted postdoctoral research at the University of Houston. Dr. Andurkar has published numerous papers and made several presentations in this field. He holds a US patent in the area of anticonvulsant drugs and is on the advisory boards of several companies. Nancy Chew - Regulatory • A serial entrepreneur, veteran business leader, biochemist and Pharmacologist by education, Regulatory expert, Several top honors & award winner and Advisor to numerous Life Sciences companies. Nancy's accomplishments and achievements of over 39 years would take several pages to detail.
  17. 17. Lifesciences Catalyst17 Aagami Associate Partners Dr. Hemant Sabharwal M.D., Ph.D. – Founder - Laktobiotics •15 years of extensive global experience in the Academia and Pharma Industry. Lived and worked in the Middle East, Egypt, Scandinavia, India, and the US. He is also Adjunct Faculty in Department of Medical Microbiology and Immunology, Streptococcal vaccine development, Rockefeller University, New York, NY. To his credit, he has more than 20 publications in peer reviewed Medical and Scientific journals. In the past, he has worked with prestigious institutions such as Institute for Cancer Prevention, NY, Mount Sinai Medical Center, NY, Lund University, Sweden, MonoCarb AB, Sweden, BioCarb AB, Sweden Anant Kataria – Founder Partner, Sagacious Research •Anant's expertise lies in supporting Patent Practitioners/Consultants, Patent Licensing Firms/Executives, Law firms in US and Europe by providing a cost-effective back-end team for all their patent related needs. His past work experience is a blend of Intellectual Property Research (IP) in various technical domains and R&D in Automobile Industry. Vyom Shah, Founder, Phronesis Strategies •Vyom has worked with companies such as PwC and TCS. With 9+ years of experience, he has extensively worked on several consulting and research cases including NPV valuations across diverse verticals and has served clients ranging from Fortune 500 companies to SMEs, supporting end-to-end engagement lifecycle. He holds an MBA from Lancaster University Management School, UK, specialising in Strategy and Management Consulting and is a qualified Chartered Accountant. Faiz Wahid - Co-founder, pManifold Research and Consulting •Faiz started pManifold in 2010 focusing on research, consulting and stakeholder engagement services. Under his leadership the firm has conducted over 10000+ primary customer interviews for various cross sector companies. He holds an MBA from HEC Paris and was an international scholar at the Darden School of Business of the University of Virginia. He also holds a masters in engineering from BITS Pilani and bachelors in engineering from VNIT Nagpur.
  18. 18. Offerings in Market/ Business Research Competitive Landscape Assessments Analysis of Portfolio and Opportunities identification Price Discovery Research Due Diligence IP and Regulatory Research Financial Modeling, NPV valuations New Market Entry strategy Market development strategy 18 Lifesciences Catalyst
  19. 19. Research Methodology Study/ Research •Primary •Interviews with different stakeholders in the Value chain including opinion leaders, vendors and customers •Proceedings of Industry events, press conferences and workshops •Surveys /studies •Secondary •Company websites, social media, blogs, forums and groups •Business directories and databases •Online and offline libraries and government data •Economic and Demographic information, Census •Case studies, Reference Customers, vendors, and associations Analysis •Qualitative •Policy and Regulatory environment •Competitive Landscape Assessment (CLA) •Business Analysis, Industry Analysis •Trends & Drivers, •Challenges and Risks •Quantitative •Market Sizing, Segmentation and Forecasting •Market share and Opportunity Analysis Reporting •Deliverables •Whitepapers •Industry Reports •Investment Models •Trend Reports •Tracking Reports •Competitive Report •Price Discovery Report •Corporate Profiles •Forecasts •Guesstimates •NPV Valuation •Client Presentation and clarifications on client questions Assess, Analyze, Derive, Synthesize, Report 19 Lifesciences Catalyst
  20. 20. Select Case Studies  Technology Licensing  Strategic Consulting  Business and Market Research Lifesciences Catalyst20
  21. 21. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Exclusive Worldwide Licensing for a Fragrance and Flavors Technology  The University developed an improved process to make Safranal faster, cheaper, and greener.  After patenting it they were finding it difficult to out license it even after more than 2 years of trying . 21 Technology Licensing Office of a reputed University from Chicago area  Aagami deployed a senior consultant to understand and capture important details about the asset / technology  Identified relevant companies in India and elsewhere.  Shortlisted 68 companies and sent them customized ‘Elevator Pitch’ (EP)  After several follow ups on phone calls and emails, coordinated CDAs and conference calls with several interested Companies and brought 3 companies on term sheet level discussions  Aagami supported in structuring and negotiating the deal discussions.  Finally established the partnership within 6 months from the start date  Technology licensing partnerships made with 2 companies in India in 6 months  Client said: “It takes a lot of time and people to pull off an agreement like this, ….. we’re very pleased that we were able to align ourselves with these two reputable international companies.” flavor-and-fragrance-research-goes-global/ Lifesciences Catalyst
  22. 22. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Study of Market Potential and Prospective Partners in India for hand- held qPCR Diagnostic Device  A mobile, lightweight molecular diagnostic technology and device was developed at the University. Its Innovation center wanted to study the market potential in India.  As per Aagami’s suggestion, client agreed to include regulatory overview and potential partners in the study. 22 Innovation Center of a New Zealand University focused on Health Sciences  Aagami involved a team of a senior and a junior researcher to conduct secondary and primary research to assess and collect market data.  Identified Competitors and their product ranges and also did a brief comparison analysis.  Prepared a crisp and concise report with data, analysis and recommendations  Also prepared a regulatory overview document  Captured the potential end users of the product as well as shortlisted potential partners  Offered consulting support for Partnership Development and India Market Entry with a clearly defined Partnering Strategy and roadmap to achieve the goal.  The report helped the University in determining conclusively on India market initiative.  Pleased with the report, the University appointed Aagami to find a licensing partner in India Lifesciences Catalyst
  23. 23. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Global NPV of Technology (in USD Million) (P) Pessimistic Scenario Discount rate 8.60% Year 2012 2013 2014 2015 2016 2017 2018 Time 0 1 2 3 4 5 6 Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93 Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19 Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98 Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57 Commercialisation Costs 400.00 - - - - - - Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11 Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55 Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56 Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61 Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44 NPV 1,524.77 Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform  Client wanted to commercialize ground breaking technology in the MI Diagnostics field, and wanted to know its commercial potential so that suitable licensing fees and model could be determined and also value could be showcased to Licensees 23 Innovative technology company spun out of a University  Aagami involved a team of a senior consultant part time and a business analyst full time to conduct primary and secondary research involving domain specialists to capture current market scenario.  Performed competitive benchmarking to assess a Relative Cost Benefit Index used later for determining technology platform (product) pricing.  Projected annual demand for next ten years in three different scenarios - Median, Optimistic and Pessimistic across multiple disease categories.  Forecasted Global Average Selling Price (ASP) and Cost associated with capex and opex  Validated commercializing options and measured incremental financial scenario for potential licensees  Determined the Global Net Present Value (NPV) and created Financial models  NPV of the technology and indicative licensing fees, along with several insights generated, served as conclusive guidance to the client for deal-making and negotiations.  The client was delighted which also resulted in repeat assignments Lifesciences Catalyst
  24. 24. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Technology Out-licensing of Transdermal Drug Delivery Technology with 3 Indian Companies  To Out-License TPM® Technology and Co-Develop in clinic products using proprietary Delivery technology and market such products in India and possibly larger region. 24 Technology development Company from Australia  Aagami scanned numerous companies and got 10 relevant companies interested.  Discussion with 8 companies progressed.  Took client to India 3 times for term sheet level meetings and deal signing.  Facilitated entire evaluation and deal structuring process  Aagami made sure testing and other protocols were honoured before deal was made.  During the process Aagami ensured clear understanding despite socio cultural differences in styles of working.  Deals with 3 global companies of India The first deal was struck for diclofenac topical gel formulation containing TPM platform. The Indian partner not only launched their own product but also out licensed to a major western pharma. The second alliance was struck for use in Skin Whitening and under eye cream. Third deal - Aagami was able to facilitate a new business model with this prospect, who using client technology increased bio availability as well as stability of a specific antibiotic. Lifesciences Catalyst
  25. 25. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Establishing Partnerships for Development and Commercialisation of Novel Class of Protein Drugs  Innovator partners in India to collaborate on a new class of proteins - Anticalins® to develop various programs in Oncology and Ophthalmology. 25 German Biotech company making safer, effective and differentiated Novel drugs  Aagami identified right partners, and took them to 7 interested companies for Anticalins®  With focused efforts 3 companies moved to term sheet level discussions. Aagami kept facilitating and persevering. 2 companies remained for final negotiations.  Aagami maintained its spirits and perseverance knowing Indian ways of working; even when client was ready to give up as per Western ways.  Finally co development partnership happened in next few months with one company in Oncology.  Second company took more time and couple of visits before signing co-development deal for ophthalmic therapy.  Client signed co-development deals with 2 companies in Oct and Dec 2013 respectively  Right companies, right advice, structure, perseverance and commitment were the key success factor. in making it happen.  Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of India.  It brought repeat and referral business to Aagami. Lifesciences Catalyst
  26. 26. Lifesciences Catalyst26 USA (Head Office) Aagami, Inc. 2135 City Gate Lane Suite 300 Naperville, IL 60653 P: +1-630-364-1837 INDIA Aagami 741, Nelson Square Nagpur MH 440013 P: +91-712-258-6678 Dinesh Jain Email: M: +1 630-853-3520 Godwyn Francis Email: M: +91-787-501-6957 CONTACT © Aagami, Inc. 2015 | All rights reserved Meet us at: